FDA to evaluate sBLA of DUPIXENT for Asthama patients
Regeneron Pharmaceuticals and Sanofi claimed that the U.S Food and Drug Administration has considered to assess the supplemental Biologics License Application (sBLA) of DUPIXENT as an…
Read More...
Read More...